Drug Profile
Tadalafil oral film - Aquestive Therapeutics
Alternative Names: AQST-119; ExordiaLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator MonoSol Rx
- Developer Aquestive Therapeutics
- Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Erectile dysfunction
Most Recent Events
- 15 Feb 2022 Tadalafil is still in preregistration stage for Erectile dysfunction in USA (Aquestive Therapeutics pipeline, February 2022)
- 29 Sep 2021 Aquestive Therapeutics and IntelGenx Corp. enter into an definitive license and supply agreement with an Undisclosed company to market tadalafil oral films for Erectile dysfunction and Benign prostatic hyperplasia in USA
- 01 Sep 2019 IntelGenx plans to launch tadalafil oral film for the treatment of Erectile dysfunction in USA, in 2021